FDA approves drug from transgenic chicken


a CD20-targeting antibody, for the treatment of B cell proliferative disorders including non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Its Phase III candidate, produced in the milk of modified goats, could be the first ‘farmaceutical’ antibody to make it to market. rEVO’s factor VIIa eptacog alfa, produced in the milk of transgenic rabbits, is in… (More)
DOI: 10.1038/nrd.2015.42


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics